Aims CF101 demonstrated a marked anti-inflammatory effect in Phase 2 studies conducted in patients with rheumatoid arthritis and dry eye syndrome. The aim of this study was to evaluate the safety and efficacy of CF101 for the treatment of patients with moderate to severe plaque-type psoriasis.
Materials and methods This was a phase 2, multicentre, randomized, double-blind, dose-ranging, placebo-controlled study. Seventy five patients with moderate to severe plaque-type psoriasis were enrolled, randomized and treated with CF101 (1, 2, or 4 mg) or placebo administered orally twice daily for 12 weeks. Safety and change ...
Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial is a post from: Skincare
Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial via BuzzBlazer.com
No comments:
Post a Comment